Global Emetogenic Drugs Market, By Class (Serotonin Receptor Antagonists (5-HT3 RAS), Neurokinin-1 Receptor Antagonist (NK1 RAS), 5HT3 RA/NK1 RA Combination, Corticosteroids, Olanzapine, Others), Type of Emesis (Acute, Delayed, Anticipatory, Breakthrough, Refractory, Chronic, Others), Application (Highly Emetogenic Chemotherapy, Moderately Emetogenic Chemotherapy, Low Emetogenic Chemotherapy, Other), Drug Type (Branded, Generic), End-Users (Hospitals, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Others) – Industry Trends and Forecast to 2030.
Emetogenic Drugs Market Analysis and Size
Emerging economies are the major markets for emetogenic drugs due to the expansion of healthcare infrastructure in these economies. The growing occurrence of cancer and gastroenteritis globally, the increase in R&D activities, and the identification of several new drug targets have been positively affecting the growth of the market. The drugs are available in numerous forms such as intravenous, intramuscular, and subcutaneous injections.
Data Bridge Market Research analyses a growth rate in the emetogenic drugs market in the forecast period 2023-2030. The expected CAGR of emetogenic drugs market is tend to be around 14.2% in the mentioned forecast period. The market was valued at USD 1371.50 million in 2022, and it would grow upto USD 3967.57 million by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Emetogenic Drugs Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Class (Serotonin Receptor Antagonists (5-HT3 RAS), Neurokinin-1 Receptor Antagonist (NK1 RAS), 5HT3 RA/NK1 RA Combination, Corticosteroids, Olanzapine, Others), Type of Emesis (Acute, Delayed, Anticipatory, Breakthrough, Refractory, Chronic, Others), Application (Highly Emetogenic Chemotherapy, Moderately Emetogenic Chemotherapy, Low Emetogenic Chemotherapy, Other), Drug Type (Branded, Generic), End-Users (Hospitals, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Heron Therapeutics, Inc. (U.S.), Sandoz International GmbH (Switzerland), Merck & Co., Inc. (U.S.), Eisai Co., Ltd (Japan), Teva Pharmaceutical Industries Ltd. (Israel), Qilu Pharmaceutical Co.,Ltd (China), F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), GSK plc (U.K.), Mundipharma International (U.K.), Baxter (U.S.), Bayer AG (Germany), Cipla Inc (U.S.), Sanofi (France), Sun Pharmaceutical Industries Ltd. (India)
|
|
Market Opportunities
|
|
Market Definition
Emetogenic symptoms are associated with nausea and vomiting related to the cancer treatment such as chemotherapy, radiation therapy and drug therapy. Nausea and vomiting are the major side effects of cancer therapy. It is significant that nausea and vomiting must be controlled so the patient can continue the treatment and have a better quality of life. Majorly nausea and vomiting induced by patients on chemotherapy and radiation therapy of the brain, gastrointestinal tract, or liver also cause nausea and vomiting.
Global Emetogenic Drugs Market Dynamics
Drivers
- High Prevalence of Cancer
As per the Cancer Statistics by the National Cancer Institute, in 2020, an assessed 1,806,590 new cases of cancer were diagnosed in the U.S. and 606,520 people died from the disease. An estimated 16,850 children and adolescents aged between 0 to 19 years were diagnosed with cancer, and 1,730 died of the same disease. Likewise, the Centers for Disease Control and Prevention reported around 179 million cases of acute gastroenteritis (AGE) occur annually in the U.S.. In the U.S. and other regions, 2-23% of children with acute gastroenteritis are treated with antiemetics, as per the reports of the American Academy of Pediatrics, 2020.
- Launch of New Drugs
Several drug launches by top market players boost the growth of the market. For instance, in September 2020, Sandoz, a Novartis division, launched generic Fosaprepitant, an anti-emetic drug used to prevent nausea and vomiting induced by chemotherapy in the U.S., increasing hospital offerings and strategically intensifying its injectables portfolio.
Opportunities
- Increased Strategic Alliances Between Market Players
There have been strategic activities such as product development, mergers, approvals, and acquisitions by major market players operating within the market are expected to boost the segment growth throughout the forecast period. For instance, in January 2022, Cumberland Pharmaceuticals, which is a specialty pharmaceutical company, acquired Sancuso, which is an oncology-supportive care medicine from Kyowa Kirin North America. Sancuso is the first and only FDA-approved Granisetron transdermal prescription patch used for the prevention of nausea and vomiting in patients who are receiving different types of chemotherapy treatment.
- Rising Demand of Oral Drugs
Oral emetogenic drugs are crating a greater market space as they prevent or treat nausea and vomiting. They work by blocking signals from the brain to the stomach which can cause these symptoms. There are several types of drugs such as ondansetron, prochlorperazine, and metoclopramide.
Restraints/Challenges
- High Cost of Emetogenic Drugs
The huge cost associated with these drugs hamper the growth of the market. There are various drugs such as Neurokinin-1 Receptor Antagonist (NK1 RAS), 5HT3 RA/NK1 RA combination, corticosteroids which cost quite high and thus restrict the marke growth.
This emetogenic drugs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the emetogenic drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Global Emetogenic Drugs Market
The COVID-19 pandemic has had a positive impact on the emetogenic drugs market. The increased cases of SARS-CoV-2 have increased the use of antiemetics to treat nausea and vomiting induced by COVID-19 or any other medication. For instance, in a study titled "Current Knowledge and recent advances in Intracellular Emetic Signaling System" published in The International Journal of Clinical Practice, 2021, it was witnessed that the use of antiemetics was majorly increased during COVID-19 to treat nausea and vomiting. It was also used in COVID-19 hospitalized patients who might be undergoing open surgery and thus more prone to nausea and vomiting. Thus, the COVID-19 outbreak positively impacted the market growth.
Recent Development
- In April 2022, Evoke Pharma, Inc., was granted new drug product exclusivity by the U.S. FDA for Gimoti nasal spray. Evoke now has exclusive marketing privileges over three years from the initial approval date under the Hatch-Waxman Act to protect the product from generic drug competition. Metoclopramide is a dopamine antagonist WHICHis used as a potent antiemetic drug
- In February 2022, Acacia Pharmaceutical’s Barhemsys received US-FDA approval. It is an intravenous formulation of amisulpride for the treatment of postoperative nausea and vomiting in patients that didn’t respond to treatment with an antiemetic from a different class. The company is in commercial preparations and is expected to launch Barhemsys in the second half of 2022.
Global Emetogenic Drugs Market Scope
The emetogenic drugs market is segmented on the basis of class, types of emesis, application, drug type, end-user and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Class
- Serotonin Receptor Antagonists (5-HT3 RAS)
- Neurokinin-1 Receptor Antagonist (NK1 RAS)
- 5HT3 RA/NK1 RA Combination
- Corticosteroids
- Olanzapine
- Others
Types of Emesis
- Acute
- Delayed
- Anticipatory
- Breakthrough
- Refractory
- Chronic
- Others
Application
- Highly Emetogenic Chemotherapy
- Moderately Emetogenic Chemotherapy
- Low Emetogenic Chemotherapy
- Other
Drug Type
- Branded
- Generic
End-Users
- Hospitals
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Others
Emetogenic Drugs Market Regional Analysis/Insights
The emetogenic drugs market is analyzed and market size insights and trends are provided by class, types of emesis, application, drug type, end-user and distribution channel as referenced above.
The major countries covered in the emetogenic drugs market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the market due to increased healthcare and R&D expenditure and presence of skilled professionals
Asia-Pacific is expected to account for the largest market share due to increased prevalence of cancer and rapidly improving healthcare infrastructure in the region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Emetogenic Drugs Market Share Analysis
The emetogenic drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to emetogenic drugs market
Key players operating in the emetogenic drugs market include:
- Heron Therapeutics, Inc.(U.S.)
- Sandoz International GmbH (Switzerland)
- Merck & Co., Inc. (U.S.)
- Eisai Co., Ltd (Japan)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Qilu Pharmaceutical Co.,Ltd (China)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Mylan N.V. (U.S.)
- GSK plc (U.K.)
- Mundipharma International (U.K.)
- Baxter (U.S.)
- Bayer AG (Germany)
- Cipla Inc (U.S.)
- Sanofi. (France)
- Sun Pharmaceutical Industries Ltd. (India)
SKU-